ArticleNature communications2025
Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes.
Ana Lledó-Delgado et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
8 papers cite it
this papercites it
ArticleNature communications2025
Ana Lledó-Delgado et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.